Cargando…

Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

BACKGROUND: Dalteparin, a low-molecular-weight heparin, has anticoagulant and anti-angiogenic activity. This study investigated whether dalteparin reduced coronary artery lesion (CAL) prevalence, and resistance to intravenous immunoglobulin (IVIG) therapy in Kawasaki disease (KD). METHODS: This retr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inamo, Yasuji, Saito, Katsuya, Hasegawa, Maki, Hayashi, Rika, Nakamura, Takahiro, Abe, Osamu, Ishikawa, Teruaki, Yoshino, Yayoi, Hashimoto, Koji, Fuchigami, Tatsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909916/ https://www.ncbi.nlm.nih.gov/pubmed/24479564 http://dx.doi.org/10.1186/1471-2431-14-27

Ejemplares similares

Bronchial Casts and Pandemic (H1N1) 2009 Virus Infection
por: Hasegawa, Maki, et al.
Publicado: (2010)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

Protein-losing enteropathy associated with Henoch-Schönlein purpura
por: Nakamura, Ayako, et al.
Publicado: (2010)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo
por: NORRBY, KLAS, et al.
Publicado: (2010)

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts
por: Winkler, Tobias, et al.
Publicado: (2011)

Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical Strategies
por: Bisio, Antonella, et al.
Publicado: (2017)

AZD-1222/dalteparin-sodium/heparin: Venous thrombosis, thrombocytopenia and lack of efficacy: 5 case reports
Publicado: (2021)

Pandemic (H1N1) 2009–associated Pneumonia in Children, Japan
por: Hasegawa, Maki, et al.
Publicado: (2011)

Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study
por: Artang, Ramin, et al.
Publicado: (2009)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Dalteparin-sodium: Chest wall haematoma: case report
Publicado: (2022)

Low serum alkaline phosphatase activity in Kikuchi-Fujimoto disease
por: Inamo, Yasuji
Publicado: (2017)

The Difficulty of Diagnosing Kikuchi-Fujimoto Disease in Infants and Children Under Six Years Old: Case Report and Literature Review
por: Inamo, Yasuji
Publicado: (2020)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

The effect of dalteparin versus unfractionated heparin on the levels of troponin I and creatine kinase isoenzyme MB in elective percutaneous coronary intervention: a multicenter study
por: Zhang, Guangming, et al.
Publicado: (2014)

Bilateral spontaneous, simultaneous lower extremity hematomas in a patient on dalteparin()
por: Daggett, J.R., et al.
Publicado: (2013)

Increases in Acute Phase Reactants in a Patient with Scurvy Despite No Inflammation: Review of Literature
por: Kimura, Kaori, et al.
Publicado: (2019)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Use of Adjunctive Therapy in Acute Kawasaki Disease in Latin America
por: Fortuna-Reyna, Brenda, et al.
Publicado: (2020)

Hypoxia and the Anticoagulants Dalteparin and Acetylsalicylic Acid Affect Human Placental Amino Acid Transport
por: Kleppa, Marc-Jens, et al.
Publicado: (2014)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

A Case Report of Turner Syndrome with Graves’ Disease during Recombinant Human GH Therapy and Review of Literature
por: Nakagawa, Makio, et al.
Publicado: (2006)

Enhanced effect of fibroblast growth factor-2-containing dalteparin/protamine nanoparticles on hair growth
por: Takabayashi, Yuki, et al.
Publicado: (2016)

Dalteparin as a Novel Therapeutic Agent to Prevent Diabetic Encephalopathy by Targeting Oxidative Stress and Inflammation
por: Zeinivand, Motahareh, et al.
Publicado: (2020)

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022)

In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia
por: Nygaard, Søren, et al.
Publicado: (2023)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Invasive Community-Acquired Methicillin-Resistant Staphylococcus aureus in a Japanese Girl with Disseminating Multiple Organ Infection: A Case Report and Review of Japanese Pediatric Cases
por: Yonezawa, Ryuta, et al.
Publicado: (2015)

Dalteparin reduces ischemia/reperfusion-induced liver injury in rats by increasing the hepatic tissue level of prostacyclin
por: Uchiba, M, et al.
Publicado: (2003)

Kawasaki Disease Following Severe Sunburn Injury
por: Okada, Seigo, et al.
Publicado: (2020)

Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan
por: Iio, Kyohei, et al.
Publicado: (2021)

Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema
por: Rommers, M, et al.
Publicado: (2005)

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
por: de Jong, Lisa A, et al.
Publicado: (2020)

Dalteparin sodium: Rectus abdominal muscle haematoma, left gluteal muscle haematoma and haemoperitoneum: 3 case reports
Publicado: (2021)

Size-tunable drug-delivery capsules composed of a magnetic nanoshell
por: Fuchigami, Teruaki, et al.
Publicado: (2012)

Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
por: Rommers, Mirjam K, et al.
Publicado: (2006)

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
por: Dranitsaris, George, et al.
Publicado: (2011)

Chloroquine/dalteparin sodium/hydroxycarbamide: Prolongation of the QTc interval secondary to off-label use and lack of efficacy: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p5au2907anahu72dtarf3v1p9k